Skip to content
KYAN Therapeutics

KYAN Therapeutics

KYAN’s mission is to unlock the full potential of combination therapies.

  • About
  • Platform
  • News
  • Team
  • Partners
  • Contact

Category: Lymphoma

AI Platform Aids Treatment for Relapsed Lymphoma

July 25, 2020August 23, 2021 kyanetics

An application of our technology was recently featured in The Straits Times. You can read more about it here: https://www.straitstimes.com/singapore/ai-platform-aids-treatment-for-relapsed-lymphoma.

Lymphoma, Optim.AI Platform artificial intelligence, lymphoma, platform

Recent Posts

  • KYAN Therapeutics Announces Collaboration with Institute of Molecular and Cell Biology for Accelerated Drug Discovery and Development of Nucleic Acids
  • KYAN Therapeutics Exclusively Licenses Small Molecule
  • AI Platform Aids Treatment for Relapsed Lymphoma
  • Global Release of Powbab Liver Cleanse Detox

Categories

  • Consumer Health
  • Drug Development
  • Lymphoma
  • Nucleic Acids
  • Optim.AI Platform
Copyright © 2021. KYAN Therapeutics, Inc. All Rights Reserved.